Prostate Cancer Patients Can Improve Bone Health With Osteoporosis Medications August 8, 2017 Men with non-metastatic prostate cancer who receive androgen deprivation therapy (ADT) risk loss of bone mineral density (BMD) and fractures, but both bisphosphonates and denosumab can improve their bone health, according to a new systematic review.Read more.Source: Cancer Network Prostate Cancer News
Men with non-metastatic prostate cancer who receive androgen deprivation therapy (ADT) risk loss of bone mineral density (BMD) and fractures, but both bisphosphonates and denosumab can improve their bone health, according to a new systematic review.Read more.Source: Cancer Network
Complete the Survey
